scholarly journals Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data

Lung Cancer ◽  
2012 ◽  
Vol 77 (1) ◽  
pp. 168-175 ◽  
Author(s):  
María S. Degese ◽  
Javier E. Mendizabal ◽  
Norberto A. Gandini ◽  
J. Silvio Gutkind ◽  
Alfredo Molinolo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Heme Oxygenase ◽  
Clinical Data ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Heme Oxygenase 1 ◽  
Small Cell Lung

Non-competitive heme oxygenase-1 activity inhibitor reduces non-small cell lung cancer glutathione content and regulates cell proliferation

2020 ◽  
Vol 47 (3) ◽  
pp. 1949-1964 ◽  
Author(s):  
Mariarita Spampinato ◽  
Giuseppe Sferrazzo ◽  
Valeria Pittalà ◽  
Michelino Di Rosa ◽  
Luca Vanella ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Proliferation ◽  
Small Cell Lung Cancer ◽  
Heme Oxygenase ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Heme Oxygenase 1 ◽  
Small Cell Lung

scholarly journals Tin Mesoporphyrin Selectively Reduces Non-Small-Cell Lung Cancer Cell Line A549 Proliferation by Interfering with Heme Oxygenase and Glutathione Systems

Biomolecules ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 917
Author(s):  
Valeria Sorrenti ◽  
Agata Grazia D’Amico ◽  
Ignazio Barbagallo ◽  
Valeria Consoli ◽  
Salvo Grosso ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Line ◽  
Heme Oxygenase ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Nsclc Cell ◽  
Antioxidant Systems ◽  
Nsclc Cell Line ◽  
Small Cell Lung

In order to maintain redox homeostasis, non-small-cell lung cancer (NSCLC) increases the activation of many antioxidant systems, including the heme-oxygenase (HO) system. The overexpression of HO-1 has been often associated with chemoresistance and tumor aggressiveness. Our results clearly showed an overexpression of the HO-1 protein in A549 NSCLC cell lines compared to that in non-cancerous cells. Thus, we hypothesized that “off-label” use of tin mesoporphyrin, a well-known HO activity inhibitor clinically used for neonatal hyperbilirubinemia, has potential use as an anti-cancer agent. The pharmacological inhibition of HO activity caused a reduction in cell proliferation and migration of A549. SnMP treatment caused an increase in oxidative stress, as demonstrated by the upregulation of reactive oxygen species (ROS) and the depletion of glutathione (GSH) content. To support these data, Western blot analysis was performed to analyze glucose-6-phosphate dehydrogenase (G6PD), TP53-induced glycolysis and the apoptosis regulator (TIGAR), and the glutamate cysteine ligase catalytic (GCLC) subunit, as they represent the main regulators of the pentose phosphate pathway (PPP) and glutathione synthesis, respectively. NCI-H292, a subtype of the NSCLC cell line, did not respond to SnMP treatment, possibly due to low basal levels of HO-1, suggesting a cellular-dependent antitumorigenic effect. Altogether, our results suggest HO activity inhibition may represent a potential target for selective chemotherapy in lung cancer subtypes.

Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data

2020 ◽  
Vol 477 (2) ◽  
pp. 207-217 ◽  
Author(s):  
Eleni A. Karatrasoglou ◽  
Ilenia Chatziandreou ◽  
Stratigoula Sakellariou ◽  
Konstantinos Stamopoulos ◽  
Nikolaos Kavantzas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Clinical Data ◽  
Cell Lung Cancer ◽  
Gene Mutations ◽  
Small Cell ◽  
Driver Gene ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document